AR076556A1 - Formas estables de n-(2,6-dimetil-4-morfolin-4-il-fenil) -3,3 -dimetil-butiramida - Google Patents

Formas estables de n-(2,6-dimetil-4-morfolin-4-il-fenil) -3,3 -dimetil-butiramida

Info

Publication number
AR076556A1
AR076556A1 ARP100101588A ARP100101588A AR076556A1 AR 076556 A1 AR076556 A1 AR 076556A1 AR P100101588 A ARP100101588 A AR P100101588A AR P100101588 A ARP100101588 A AR P100101588A AR 076556 A1 AR076556 A1 AR 076556A1
Authority
AR
Argentina
Prior art keywords
dimetil
butiramida
morfolin
fenil
stable forms
Prior art date
Application number
ARP100101588A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42237259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR076556(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR076556A1 publication Critical patent/AR076556A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporcionan formas polimorficas de N-(2,6-dimetil-4-morfolin-4-il-fenil)-3,3-dimetil-butiramida, junto con un proceso para la elaboracion de dicho compuesto. Forma cristalina con XRPX en 10,36; 12,67; 28,64 y 29,98 (s2theta); forma cristalina con XRPX en 8,68; 18,09; 22,60 y 30,62 (s2theta); forma cristalina con XRPX en 8,63; 22,26; 23,40 y 30,49 (s2theta); composiciones farmacéuticas y uso para trastornos convulsivos, depresion, bipolar y esquizofrenia.
ARP100101588A 2009-05-11 2010-05-10 Formas estables de n-(2,6-dimetil-4-morfolin-4-il-fenil) -3,3 -dimetil-butiramida AR076556A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200900597 2009-05-11

Publications (1)

Publication Number Publication Date
AR076556A1 true AR076556A1 (es) 2011-06-22

Family

ID=42237259

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101588A AR076556A1 (es) 2009-05-11 2010-05-10 Formas estables de n-(2,6-dimetil-4-morfolin-4-il-fenil) -3,3 -dimetil-butiramida

Country Status (23)

Country Link
EP (1) EP2430008A2 (es)
JP (1) JP2012526152A (es)
KR (1) KR20120022934A (es)
CN (1) CN102459208A (es)
AR (1) AR076556A1 (es)
AU (1) AU2010246724B2 (es)
BR (1) BRPI1013930A2 (es)
CA (1) CA2761383A1 (es)
CL (1) CL2011002814A1 (es)
CO (1) CO6460741A2 (es)
CR (1) CR20110590A (es)
DO (1) DOP2011000351A (es)
EA (1) EA201171381A1 (es)
GE (1) GEP20146006B (es)
IL (1) IL216148A0 (es)
MA (1) MA33351B1 (es)
MX (1) MX2011011885A (es)
NZ (1) NZ596738A (es)
SG (1) SG175968A1 (es)
TN (1) TN2011000557A1 (es)
TW (1) TW201041857A (es)
WO (1) WO2010130260A2 (es)
ZA (1) ZA201108112B (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI349666B (en) * 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
MX2009002002A (es) * 2006-08-23 2009-07-22 Valeant Pharmaceuticals Int Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potasio.
CA2694887A1 (en) * 2007-08-01 2009-02-05 Henriette Husum Bak-Jensen Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted

Also Published As

Publication number Publication date
JP2012526152A (ja) 2012-10-25
AU2010246724B2 (en) 2013-03-21
TN2011000557A1 (en) 2013-05-24
CL2011002814A1 (es) 2012-04-13
IL216148A0 (en) 2012-01-31
SG175968A1 (en) 2011-12-29
WO2010130260A2 (en) 2010-11-18
MX2011011885A (es) 2011-12-06
MA33351B1 (fr) 2012-06-01
WO2010130260A9 (en) 2012-10-18
BRPI1013930A2 (pt) 2019-09-24
WO2010130260A3 (en) 2011-06-16
TW201041857A (en) 2010-12-01
DOP2011000351A (es) 2012-01-31
EP2430008A2 (en) 2012-03-21
NZ596738A (en) 2013-04-26
CR20110590A (es) 2012-02-22
GEP20146006B (en) 2014-01-10
CA2761383A1 (en) 2010-11-18
EA201171381A1 (ru) 2012-05-30
CN102459208A (zh) 2012-05-16
CO6460741A2 (es) 2012-06-15
AU2010246724A1 (en) 2011-12-08
KR20120022934A (ko) 2012-03-12
ZA201108112B (en) 2013-01-30

Similar Documents

Publication Publication Date Title
ECSP078055A (es) Formas sólidas cristalinas de tigeciclina y métodos para preparar las mismas
AR061311A1 (es) Procesos para preparar clorhidrato de cinacalcet y formas polimorficas del mismo
MX2010004576A (es) Derivados de pirimidina novedosos.
UY31344A1 (es) Metansulfonamidas n-(3-ter-butil-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-2-metoxi-aril) sustituidas, solvatos, hidratos, formas cristalinas y sus sales farmacéuticamente aceptables,proceso de preparación,composiciones y aplicaciones.
BRPI0816553A2 (pt) "composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto"
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
CR10157A (es) Compuestos químicos
TW200942524A (en) Novel aminomethyl benzene derivatives
CL2012002540A1 (es) Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras.
UY34008A (es) ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?.
ECSP10010347A (es) (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina
CO6551754A2 (es) 7-[3.5-dihidroxi-2-(3-hidrixi-5-fenil-pent-1-enil)- ciclopentil] -n-etil-hept-5-enamida(bimatoprost) en forma cristalina ii, mètodos para la preparaciòn y mètodo para su uso
UY29434A1 (es) Derivados de tetrahidronaftalina, procedimientos para su preparación y su uso como inhibidores de la inflamacinn
ECSP088740A (es) Derivados de tetrahidronaftalina, procedimientos para prepararlos y su uso como antiinflamatorios
CL2011001405A1 (es) Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina.
BR112012017188A8 (pt) composto agonista de mglu2, sua composição farmacêutica e seu uso
BRPI0515193A (pt) novos polimorfos de azabiciclohexano
BRPI0610156A2 (pt) forma micronizada de um composto, forma purificada i do composto, kit, padrão de referência, e, método de preparaçao de uma composição farmacêutica.
UY29481A1 (es) Derivados de tetrahidronaftalina, procedimientos para su preparación y su uso como antiinflamatorios.
DK1951738T3 (da) Nye krystallinske former af rostafuroxin
BRPI0605901A (pt) formas polimórficas de maleato de tegaserode
AR080203A1 (es) Formas solidas que comprenden una ciclopropilamida
AR076556A1 (es) Formas estables de n-(2,6-dimetil-4-morfolin-4-il-fenil) -3,3 -dimetil-butiramida
CL2012002541A1 (es) Compuesto cristalino hidrato del hidrobromuro de agomelatina; metodo de preparacion del compuesto; composicion farmaceutica; uso del compuesto para tratar trastornos del sueño, estres, ansiedad, depresion mayor, esquizofrenia, entre otros.
BR112013015903A2 (pt) polimorfo cristalino, processo para preparar um polimorfo, composição farmacêutica, forma purificada do polimorfo, uso de um polimorfo, processo para preparar um composto, e, composto.

Legal Events

Date Code Title Description
FB Suspension of granting procedure